 Aaron Knox
Concepts (173)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Keratin-5 | 1 | 2014 | 39 | 0.560 |
Why?
| | Receptors, Progesterone | 1 | 2014 | 339 | 0.470 |
Why?
| | Receptors, Estrogen | 1 | 2014 | 399 | 0.450 |
Why?
| | Pituitary Neoplasms | 5 | 2015 | 158 | 0.430 |
Why?
| | Phosphoribosylglycinamide Formyltransferase | 1 | 2008 | 1 | 0.390 |
Why?
| | Purines | 1 | 2008 | 168 | 0.340 |
Why?
| | Models, Biological | 1 | 2014 | 1845 | 0.310 |
Why?
| | Gonadotrophs | 4 | 2015 | 21 | 0.290 |
Why?
| | Breast Neoplasms | 1 | 2014 | 1909 | 0.250 |
Why?
| | raf Kinases | 1 | 2021 | 11 | 0.240 |
Why?
| | Bradykinin | 1 | 2001 | 52 | 0.230 |
Why?
| | Endothelial Growth Factors | 1 | 2001 | 72 | 0.230 |
Why?
| | Lymphokines | 1 | 2001 | 146 | 0.230 |
Why?
| | MAP Kinase Signaling System | 1 | 2021 | 320 | 0.200 |
Why?
| | Trachea | 1 | 2001 | 229 | 0.200 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2021 | 202 | 0.200 |
Why?
| | Pituitary Gland | 3 | 2015 | 172 | 0.190 |
Why?
| | Glioma | 1 | 2021 | 274 | 0.180 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2001 | 482 | 0.180 |
Why?
| | Adenoma | 2 | 2011 | 190 | 0.180 |
Why?
| | Mutation | 1 | 2008 | 3447 | 0.170 |
Why?
| | Models, Educational | 1 | 2015 | 100 | 0.150 |
Why?
| | Vascular Cell Adhesion Molecule-1 | 1 | 2014 | 52 | 0.140 |
Why?
| | MCF-7 Cells | 1 | 2014 | 119 | 0.140 |
Why?
| | Heterografts | 1 | 2014 | 126 | 0.140 |
Why?
| | Gene Expression Regulation, Neoplastic | 4 | 2015 | 1210 | 0.130 |
Why?
| | Small Molecule Libraries | 1 | 2014 | 83 | 0.130 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2014 | 193 | 0.130 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2014 | 197 | 0.130 |
Why?
| | Brain Neoplasms | 1 | 2021 | 960 | 0.130 |
Why?
| | Hypogonadism | 1 | 2014 | 74 | 0.130 |
Why?
| | Immunophenotyping | 1 | 2014 | 310 | 0.130 |
Why?
| | Education, Medical | 1 | 2015 | 244 | 0.120 |
Why?
| | Prolactinoma | 1 | 2011 | 10 | 0.120 |
Why?
| | Up-Regulation | 4 | 2015 | 975 | 0.110 |
Why?
| | Learning | 1 | 2015 | 373 | 0.110 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 4 | 2014 | 1123 | 0.110 |
Why?
| | Antigens, Differentiation | 1 | 2011 | 85 | 0.110 |
Why?
| | Ki-67 Antigen | 1 | 2011 | 108 | 0.110 |
Why?
| | Cell Survival | 4 | 2015 | 1188 | 0.110 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2014 | 268 | 0.110 |
Why?
| | ErbB Receptors | 1 | 2014 | 549 | 0.110 |
Why?
| | Cell Proliferation | 4 | 2015 | 2404 | 0.110 |
Why?
| | Glycoproteins | 1 | 2012 | 350 | 0.100 |
Why?
| | Oligonucleotide Array Sequence Analysis | 4 | 2015 | 835 | 0.100 |
Why?
| | Gene Expression Profiling | 2 | 2014 | 1640 | 0.100 |
Why?
| | Cell Line, Tumor | 2 | 2014 | 2936 | 0.100 |
Why?
| | Proto-Oncogene Proteins | 1 | 2014 | 716 | 0.100 |
Why?
| | Tumor Suppressor Proteins | 1 | 2011 | 297 | 0.100 |
Why?
| | Endothelial Cells | 1 | 2014 | 650 | 0.100 |
Why?
| | Cricetulus | 1 | 2008 | 107 | 0.090 |
Why?
| | Blotting, Northern | 1 | 2008 | 225 | 0.090 |
Why?
| | Biocatalysis | 1 | 2008 | 70 | 0.090 |
Why?
| | CHO Cells | 1 | 2008 | 161 | 0.090 |
Why?
| | Cricetinae | 1 | 2008 | 295 | 0.090 |
Why?
| | Clinical Competence | 1 | 2015 | 913 | 0.090 |
Why?
| | DNA, Complementary | 1 | 2008 | 299 | 0.090 |
Why?
| | Gene Dosage | 1 | 2008 | 148 | 0.090 |
Why?
| | Cell Cycle Proteins | 1 | 2012 | 574 | 0.090 |
Why?
| | Cloning, Molecular | 1 | 2008 | 599 | 0.090 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2011 | 465 | 0.080 |
Why?
| | Mice | 6 | 2014 | 15641 | 0.080 |
Why?
| | Animals | 8 | 2014 | 35394 | 0.080 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2008 | 330 | 0.080 |
Why?
| | DNA-Binding Proteins | 1 | 2014 | 1460 | 0.080 |
Why?
| | Genome | 1 | 2008 | 282 | 0.080 |
Why?
| | Transfection | 1 | 2008 | 997 | 0.080 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2008 | 416 | 0.080 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2014 | 2052 | 0.080 |
Why?
| | Cystathionine beta-Synthase | 1 | 2006 | 64 | 0.080 |
Why?
| | Sequence Analysis, DNA | 1 | 2008 | 798 | 0.070 |
Why?
| | Blotting, Western | 1 | 2008 | 1316 | 0.070 |
Why?
| | Cells, Cultured | 3 | 2014 | 4429 | 0.070 |
Why?
| | RNA, Messenger | 2 | 2011 | 2857 | 0.070 |
Why?
| | Disease Models, Animal | 1 | 2014 | 3910 | 0.070 |
Why?
| | Biomarkers | 1 | 2014 | 3501 | 0.060 |
Why?
| | Molecular Sequence Data | 1 | 2008 | 3118 | 0.060 |
Why?
| | Gene Expression | 2 | 2014 | 1588 | 0.060 |
Why?
| | Receptor, Bradykinin B2 | 1 | 2001 | 3 | 0.060 |
Why?
| | Receptors, Bradykinin | 1 | 2001 | 6 | 0.060 |
Why?
| | Bradykinin Receptor Antagonists | 1 | 2001 | 5 | 0.060 |
Why?
| | Nitrobenzenes | 1 | 2001 | 17 | 0.060 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 2001 | 86 | 0.060 |
Why?
| | Indomethacin | 1 | 2001 | 86 | 0.060 |
Why?
| | Prostaglandins | 1 | 2001 | 91 | 0.060 |
Why?
| | Cyclooxygenase Inhibitors | 1 | 2001 | 83 | 0.060 |
Why?
| | Humans | 12 | 2021 | 113846 | 0.060 |
Why?
| | Down Syndrome | 1 | 2006 | 305 | 0.060 |
Why?
| | Naphthalenes | 1 | 2001 | 60 | 0.060 |
Why?
| | Arachidonic Acid | 1 | 2001 | 139 | 0.060 |
Why?
| | Dinoprostone | 1 | 2001 | 191 | 0.060 |
Why?
| | Cyclic AMP | 1 | 2001 | 290 | 0.050 |
Why?
| | Female | 6 | 2021 | 63035 | 0.050 |
Why?
| | Protein Isoforms | 1 | 2001 | 348 | 0.050 |
Why?
| | Mice, Transgenic | 1 | 2006 | 2161 | 0.050 |
Why?
| | Protein Kinase C | 1 | 2001 | 354 | 0.050 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2001 | 517 | 0.050 |
Why?
| | Immunohistochemistry | 2 | 2014 | 1831 | 0.050 |
Why?
| | Sulfonamides | 1 | 2001 | 450 | 0.040 |
Why?
| | Enzyme Inhibitors | 1 | 2001 | 945 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2001 | 2229 | 0.040 |
Why?
| | Male | 6 | 2021 | 60993 | 0.040 |
Why?
| | Time Factors | 2 | 2011 | 7060 | 0.040 |
Why?
| | RNA | 1 | 2001 | 776 | 0.040 |
Why?
| | Tumor Stem Cell Assay | 1 | 2015 | 38 | 0.040 |
Why?
| | Cytoprotection | 1 | 2015 | 60 | 0.040 |
Why?
| | Cell Line | 2 | 2012 | 3016 | 0.040 |
Why?
| | E-Selectin | 1 | 2014 | 55 | 0.040 |
Why?
| | Mutant Proteins | 1 | 2015 | 105 | 0.040 |
Why?
| | Gene Amplification | 1 | 2015 | 107 | 0.040 |
Why?
| | Kallmann Syndrome | 1 | 2014 | 10 | 0.030 |
Why?
| | Golgi Apparatus | 1 | 2014 | 104 | 0.030 |
Why?
| | DNA Copy Number Variations | 1 | 2015 | 159 | 0.030 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2015 | 314 | 0.030 |
Why?
| | Sexual Maturation | 1 | 2014 | 55 | 0.030 |
Why?
| | Immunoblotting | 1 | 2014 | 375 | 0.030 |
Why?
| | Cell Hypoxia | 1 | 2015 | 238 | 0.030 |
Why?
| | Mice, Inbred C57BL | 2 | 2014 | 5249 | 0.030 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2015 | 235 | 0.030 |
Why?
| | Adult | 4 | 2014 | 31979 | 0.030 |
Why?
| | Educational Measurement | 1 | 2015 | 303 | 0.030 |
Why?
| | Cell Adhesion | 1 | 2014 | 474 | 0.030 |
Why?
| | Pedigree | 1 | 2014 | 518 | 0.030 |
Why?
| | Microscopy, Fluorescence | 1 | 2014 | 448 | 0.030 |
Why?
| | G2 Phase | 1 | 2012 | 41 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2015 | 442 | 0.030 |
Why?
| | RNA Interference | 1 | 2014 | 515 | 0.030 |
Why?
| | CpG Islands | 1 | 2012 | 107 | 0.030 |
Why?
| | Genes, Tumor Suppressor | 1 | 2012 | 85 | 0.030 |
Why?
| | Protein Structure, Tertiary | 1 | 2015 | 906 | 0.030 |
Why?
| | Cavernous Sinus | 1 | 2011 | 13 | 0.030 |
Why?
| | Active Transport, Cell Nucleus | 1 | 2012 | 132 | 0.030 |
Why?
| | Mitotic Index | 1 | 2011 | 28 | 0.030 |
Why?
| | Reactive Oxygen Species | 1 | 2014 | 560 | 0.030 |
Why?
| | Skull Base | 1 | 2011 | 34 | 0.030 |
Why?
| | Genetic Association Studies | 1 | 2014 | 415 | 0.030 |
Why?
| | Genes, p53 | 1 | 2011 | 74 | 0.030 |
Why?
| | Cytoplasm | 1 | 2012 | 307 | 0.030 |
Why?
| | Evidence-Based Medicine | 1 | 2015 | 728 | 0.030 |
Why?
| | Stress, Physiological | 1 | 2015 | 525 | 0.030 |
Why?
| | Tumor Burden | 1 | 2011 | 281 | 0.030 |
Why?
| | Middle Aged | 3 | 2011 | 28753 | 0.030 |
Why?
| | NF-kappa B | 1 | 2014 | 719 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2011 | 454 | 0.030 |
Why?
| | Cell Division | 1 | 2012 | 880 | 0.030 |
Why?
| | Adolescent | 2 | 2021 | 18736 | 0.020 |
Why?
| | Gonadotropins, Pituitary | 1 | 2008 | 17 | 0.020 |
Why?
| | Curriculum | 1 | 2015 | 818 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2014 | 1251 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2012 | 1100 | 0.020 |
Why?
| | DNA Damage | 1 | 2011 | 373 | 0.020 |
Why?
| | Radiography | 1 | 2011 | 828 | 0.020 |
Why?
| | Signal Transduction | 2 | 2015 | 4923 | 0.020 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2008 | 378 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2012 | 1259 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2014 | 2893 | 0.020 |
Why?
| | Diploidy | 1 | 2006 | 13 | 0.020 |
Why?
| | Tumor Cells, Cultured | 1 | 2008 | 1041 | 0.020 |
Why?
| | Chromosomes, Human, Pair 21 | 1 | 2006 | 33 | 0.020 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2011 | 789 | 0.020 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2008 | 400 | 0.020 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2006 | 330 | 0.020 |
Why?
| | Apoptosis | 1 | 2015 | 2675 | 0.020 |
Why?
| | Inflammation | 1 | 2014 | 2451 | 0.020 |
Why?
| | Child | 1 | 2021 | 17711 | 0.020 |
Why?
| | Aged | 2 | 2011 | 20109 | 0.020 |
Why?
| | Cognition Disorders | 1 | 2006 | 584 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2011 | 3049 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2011 | 6796 | 0.010 |
Why?
| | DNA | 1 | 2006 | 1417 | 0.010 |
Why?
| | Young Adult | 1 | 2014 | 10971 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2011 | 9002 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2011 | 11340 | 0.010 |
Why?
|
|
Knox's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|